Amyloid β peptides (Aβ 1-40 and Aβ 1-42 ) cause cerebral degeneration also by exerting 20 antiangiogenic properties, as impairment of angiogenic factors activity and induction of 21 apoptosis and senescence in the endothelium. Amyloid peptides are known to induce 22 oxidative stress. Impairment of mitochondrial aldehyde dehydrogenase 2 (ALDH2) following 23 oxidative stress, results in accumulation of toxic aldehydes, particularly 4-hydroxynoneal (4-24 HNE). We sought to determine the role of mithocondrial ALDH2 in Aβ-related impairment 25 of angiogenesis. We hypothesized that by increasing the detoxification activity of ALDH2, 26
Summary 19
Amyloid β peptides (Aβ 1-40 and Aβ 1-42 ) cause cerebral degeneration also by exerting 20 antiangiogenic properties, as impairment of angiogenic factors activity and induction of 21 apoptosis and senescence in the endothelium. Amyloid peptides are known to induce 22 oxidative stress. Impairment of mitochondrial aldehyde dehydrogenase 2 (ALDH2) following 23 oxidative stress, results in accumulation of toxic aldehydes, particularly 4-hydroxynoneal (4-24 HNE). We sought to determine the role of mithocondrial ALDH2 in Aβ-related impairment 25 of angiogenesis. We hypothesized that by increasing the detoxification activity of ALDH2, 26
we would reduce Aβ-driven endothelial injuries and restore angiogenesis. We used a 27 selective ALDH2 activator, Alda-1, assessing its ability to repair mithocondrial dysfunction 28 in the endothelium. Treatment of human endothelial cells with Aβ 1-40 (5-50 μ M), induced loss 29 of mitochondrial membrane potential, increased cytochrome c release and ROS 30 accumulation. These events were associated with 4-HNE accumulation and decrease in 31 ALDH2 activity (40%), and resulted in disassembly of endothelial junctions, as evidenced by 32 β -catenin phosphorylation, disorganization of adherens and tight junctions, and by disruption 33 of pseudocapillary formation. Alda-1 (10-40 μ
M) abolished Aβ-induced 4-HNE 34
Introduction 43 A wealth of evidence indicates the mitochondria dysfunction is a feature common to many 44 age-related degenerative pathologies, including β amyloid-driven diseases such as 45
Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) (Lin and Beal, 2006, Cho 46 et al., 2009) . β amyloids have been shown to localize mainly at the inner mithochondrial 47 membrane, causing excessive reactive oxygen species (ROS) production (Lin and Beal, 48 2006) . Besides the respiratory chain injuries, β amyloids have been shown to enhance the 49 expression of cyclophilin D, a mitochondrial protein regulating the opening of the transition 50 pore (Du et al., 2008) , and to promote S-nitrosylation of dynamin-related protein 1, a protein 51 that governs mitochondrial dynamics (Cho et al., 2009) . β amyloids also form a complex with 52 the mitochondrial Aβ-peptide-binding alcohol dehydrogenase (ABAD), an interaction which 53 leads to accelerated cell death (Yao et al., 2011) . 54
In addition, β amyloid-induced ROS elevation activates lipid peroxidation pathways, a 55 mechanism that generates excessive amounts of higly toxic aldehydes, particularly 4-56 hydroxy-2-noneal (4-HNE) (Schneider et al., 2008) . Because of its electrophilic nature, 4-57 HNE forms stable adducts with a myriad of proteins required for mitochondrial functions 58 (Petersen and Door, 2004) . 4-HNE exerts toxic effects in a wide range of tissues, including 59 neural and cardiac tissues (Neely et al., 1999; Che-Hong et al., 2008) and endothelium 60 (Suzuki et al., 2007) . 61
Although metabolized by a number of detoxifying mechanisms, 4-HNE is a specific substrate 62 of the mitochondrial aldehyde dehydrogenase 2 (ALDH2) (Che-Hong et al., 2008; Hyun et 63 al., 2002; Mattson, 2009) . In a rat myocardial infarction model, boosting the ALDH2 activity, 64 through a novel enzyme activator, Alda-1, resulted in 60% decreased injury from the 65 ischemic damage, an effect associated with enhanced clearing of the toxic 4-HNE (Che-Hong 66 et al., 2008) . 67 β amyloid peptides, particularly the shorter vasculotropic Aβ 1-40 (hereafter termed Aβ), affect 68 brain blood vessels, altering important functions of medium and small arterioles and capillary 69 endothelium. These derangements include impairment of vasoactive tone, vascular 70 remodeling, and barrier functions, as well as suppression of the intrinsic angiogenic 71
properties of endothelium, such as responsiveness to fibroblast growth factor-2 (FGF-2), 72 FGF-2 expression, its cognate receptor FGFR1, and, also, vascular endothelial gowth factor 73 receptor2 (VEGFR2) (Revesz et al., 2003; Patel et al., 2010; Solito et al., 2009) . Collectively, 74 these alterations contribute to CAA, a pathology characterized by Aβ 1-40 deposition aroundInvestigations from various laboratories have delineated a range of Aβ-induced biochemical 77 and signal changes that underlie the disease. The observation that Aβ strongly activates the 78 intrinsic apoptotic pathway is perhaps the clearest evidence that these peptides target the 79 mitochondria to execute their toxic effects (Fossati et al., 2010) . 80
We sought to determine the role of mithocondrial ALDH2 in Aβ related impairment of 81 endothelial functions and FGF-2-mediated angiogenesis. To investigate ALDH2 in 82 angiogenic events, and in amyloid angiopathy, we used the recent identification of a novel 83 class of small molecular weight compounds that selectively interact with the mitochondrial 84 enzyme increasing its catalytic activity. Specifically, Alda-1 (benzodioxyl 85 dichlororobezamide), the prototype of compounds that activate ALDH2, inhibits the injuries 86 produced by 4-HNE in several model of oxidative stress (Che-Hong et al., 2008; Perez-Miller 87 et al., 2010) . 88
The use of this pharmacological tool enabled to delineate the role of mitochondrial ALDH2 89 in Aβ-impaired angiogenesis. The effects induced by Aβ on the endothelium have been described in numerous reports 96 (Revesz et al., 2003; Patel et al., 2010; Solito et al., 2009 ). Here we focused on the Aβ-97 induced mitochondrial dysfunction in endothelial cells, human umbilical endothelial cells 98 (HUVEC) and human brain microvascular endothelial cells (HBMEC). To characterize the 99 mitochondrial damage induced by Aβ, we evaluated a number of mitochondrial functions. Aβ 100 produced a concentration-dependent loss of mitochondrial membrane potential (Δψm), as 101 measured by JC-1 monomer levels (Fig. 1A) . The reverse peptide (Aβ 40-1 ), since did not 102 affect mitochondrial potential relative to no peptide addition (5756 ± 429 vs. 5880 ± 307, 103 fluorescence levels respectively), was used as control throughout the manuscript. There was 104 also a 7 folds increase in cytochrome c release in Aβ treated HUVEC (Fig. 1B) . Impairment 105 of mitochondrial potential affected the integrity of the electron transport system, producing a 106 marked rise of super oxide formation, detected by MitoSox (Fig. 1C) . A similar loss of Δψm, 107 as well as cytochrome c relase and ROS overproduction occurred in HBMEC exposed to Aβ 108 (Fig. 1D,E,F) . 109
To investigate the molecular mechanism of Aβ-induced mitochondrial dysfunction, we 110 determined whether the lipid-peroxidation generated aldehyde, 4-HNE, accumulates 111 following Aβ treatment. In particular, as this aldehyde is very reactive and forms adducts on 112 macromolecules, including proteins (Petersen and Door, 2004), we measured 4-HNE protein 113 adducts detected by ELISA ( Fig. 2A) and immunohistochemistry ( Fig. 2B ) in Aβ-treated 114 cells. There was a three-fold increase in 4-HNE adduct formation ( Fig. 2A and 2B, panel b) , 115 especially around the perinuclear area (Fig. 2B, panel b) . To investigate whether 4-HNE 116 adducts localized in mitochondria, we performed the double staining of 4-HNE adduct 117 formation in combination with an antibody against the TOM 20 (a traslocase of the outer 118 mitochondrial membrane; Fig. 2C, panel a) . We detected a co-localization of 4-HNE within 119 the mitochondria (Fig. 2C, panel b) , along with partial overlap of the two markers in the 120 organelles. Since ALDH2 is the main enzyme that metabolizes 4-HNE, we determined 121 whether selective activation of ALDH2 with Alda-1 would decrease the levels of 4-HNE 122 adducts. Co-treatment of HUVEC with Alda-1 and Aβ caused more than 60% decrease in 4HNE adduct accumulation ( Fig. 2A) , drastically reducing the 4-HNE associated 124 immunofluorescence ( Fig. 2B and C ; compare panels c vs. b in both figures). 125
To determine whether Aβ-induced mitochondrial dysfunction is caused by adduct 126 accumulation, we determined the benefit of Alda-1 (10-40 µM) on mitochondrial membrane 127 potential. The two highest Alda-1 concentrations provided comparable protection of 128 mitochondrial potential, whereas the lower one was ineffective (Fig. 3A) . substantially reduced ALDH2 activity by 40% (Fig. 4A) , exerting negligible effects on its 149 expression (Fig. 4B ). This reflects an ALDH2 inactivation by 4-HNE (Che-Hong et al., 150 2008), rather than a direct interaction of Aβ with the enzyme. In fact, incubation of Aβ (10-50 151 µM) with recombinant ALDH2, did not reduce its enzymatic activity (Fig. 4C ). As reported 152 (Che-Hong et al., 2008) , addition of Alda-1 to the recombinant enzyme produced a 153 significant increase of its catalytic activity (Fig. 4C) . Importantly, administration of Alda-1 154 prior Aβ treatment prevented the decline in ALDH2 activity in both HUVEC (Fig. 4E,  155 p<0.01) and in HBMEC (Fig. 4F , p< 0.05). Further, the marked expression of ALDH2compared to that of ALDH1 in HUVEC, suggests its preeminent involvement in the removal 157 of 4-HNE in endothelial cells (Fig. 4D) . To examine the possibility that reactive species other 158 than 4-HNE were involved in ALDH2 decreased activity, we used optimal concentration of 159 MnTBAP, a cell permeable superoxide dismutase (SOD) mimetic (Cantara et al., 2007) , and 160 measured ALDH2 activity in HUVEC previously exposed to Aβ. The scavenger was 161 effective in reversing Aβ-decrease ALDH2 activity, although its efficacy was lower 162 compared to that of Alda-1 (Fig. 4E, reported (Donnini et al., 2010 , Paris et al., 2005 . Here, we show that HUVEC, seeded on 195 matrigel, produce an organized pseudocapillary network (Fig. 6A, panel a, and insert i) , while 196 they fail to organize a proper architecture in the presence of Aβ (Fig. 6A, panel b) . The 197 observed cell clustering and stunted growth, occurring in the presence of Aβ, was likely due 198 to impaired cell adhesion and migration (Fig. 6A, insert ii) . Of note, only a few endothelial 199 cells enter apoptosis as documented by phosphatidylserine immunofluorescence (Fig. 3C)  200 and trypan blue staining (data not shown). Experiments on cell migration showed a 201 significantly reduced migration (40%, p< 0.01) caused by Aβ (Fig. 7A) . The severe 202 endothelial injuries observed were invariably counteracted by prior application of Alda-1. In 203 fact, the pseudocapillary architecture and cell migration were fully maintained in presence of 204 Alda-1 (Fig. 6A , panel c, and 7A) as also shown in the graph representing quantification of 205 pseudocapillaries (Fig. 6B) . 206
In the context of neovessel formation, we and others have reported that Aβ reduces the 207 expression of major endothelial growth factors, e.g. FGF-2 and VEGF, as well their capacity 208 to elicit angiogenic responses (Donnini et al., 2010 Solito 2009 , Paris et al., 2005 . We 209 therefore sought to learn whether ALDH2 activation would prevent these Aβ induced 210 injuries. Indeed, Aβ reduced endogenous FGF-2 expression in HUVEC by approximately 211 50%, an effect completely prevented by the activation of ALDH2 via Alda-1 (Fig. 7B) . Also, 212
Alda-1 restored responsiveness to exogenous FGF-2 (20 ng/ml) in the formation of the 213 network of pseudocapillaries, impaired by Aβ, as documented by the quantification of 214 pseudocapillary network formation (Fig. 6A, panels d-f, Fig. 6B ). Similarly, Alda-1 recov-215 ered the capability of endothelial cells to respond to FGF-2, when HUVEC where embedded 216 in the fibrin gel and exposed to Aβ, restoring their angiogenic phenotype ( Fig. 6C and D) . (Fig. 4C) . 239 Therefore, the sharp decline of ALDH2 enzymatic activity, noted in endothelium following 240 Aβ treatment, is clearly related to the oxidative injuries to the mitochondria, rather than a 241 direct effect of the Aβ on ALDH2. 242 This is the first study that shows the decline of ALDH2 activity in endothelial cells treated 243 with Aβ, pointing to ALDH2 activity decline as the mechanism of Aβ toxicity. Indeed, by 244 using a specific activator of ALDH2, termed Alda-1, we found that the ALDH2 recovery 245 fully restored mitochondrial functions, in terms of membrane potential and cytochrome c 246 release. Alda-1 treatment reduced 4-HNE adducts and ROS formation, and rescued Aβ-247 impaired functions of the endothelium, supporting the hypothesis that impaired detoxification 248 of biogenic aldehydes may be important in Aβ-induced vessel injuries. The molecular 249 mechanism whereby Alda-1 protects ALDH2, described in a report from one of our 250 laboratories, illustrates how the compound reduces the accessibility of 4-HNE to key cysteineresidues of the enzyme, essentially by prolonging the residence of NAD, the enzyme cofactor 252 (Perez-Miller et al., 2010) . 253
The activation of ALDH2, through Alda-1, was a remarkably efficient mean to contrast the 254 Aβ-induced injuries on the endothelium. In fact, protection was evident on both basic and 255 FGF-2-mediated endothelial functions, such as the ability of cultured endothelium to express 256 an angiogenic phenotype (pseudocapillary formation, and FGF-2 production) and to maintain 257 the barrier function. These are important determinants of endothelial viability, as they are the 258 basis of vessel remodeling and protection of the underlying tissues from toxic insults. 259
Further, since FGF-2 is an important prosurvival and pro-angiogenic factor, the 260 responsiveness to FGF-2, promoted by ALDH2 activation, is a relevant determinant of 261 endothelial angiogenic potential. 
